A novel clinically applicable biomarker for testing HRD status based on the mutational signatures: Results for the phase 2 trial of olaparib maintenance monotherapy in patients with primary high-grade ovarian carcinoma (2271)Katsutoshi Oda, Hiroyuki Aburatani, Kosei Hasegawa et al.|Gynecologic Oncology|2023Cited by 0